Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose Comparison of variant frequencies in the general population has become an essential part of the American College of Medical Genetics and Genomics (ACMG) standards and guidelines for interpreting sequence variants. We determined the optimal number of relevant ethnic controls that should be used to accurately calculate the odds ratio (OR) of genetic variants. Materials and Methods Using the ACMG guidelines, we reclassified BRCA1 and BRCA2 mutations and variants of unknown significance in 745 Korean patients susceptible to hereditary breast and ovarian cancer compared with 1,314 Korean population controls. Results We observed that the ORs were falsely inflated when we analyzed several variants using non-Korean population data. Our simulation indicated that the number of controls needed for the lower limit of a 95% confidence interval to exceed 1.0 varied according to the frequency of the variant in each patient group, with more than 820 controls needed for a variant existing in 1% of cases. Using a sufficient number of relevant population data, we could efficiently classify variants and identified the BRCA1 p.Leu1780Pro mutation as a possible pathogenic founder mutation in Korean patients. Conclusion Our study suggests that BRCA1 p.Leu1780Pro is a novel pathogenic mutation found in Korean patients. We also determined the optimal number of relevant ethnic controls needed for accurate variant classification according to the ACMG guidelines.
Abstract
Purpose Comparison of variant frequencies in the general population has become an essential part of the American College of Medical Genetics and Genomics (ACMG) standards and guidelines for interpreting sequence variants. We determined the optimal number of relevant ethnic controls that should be used to accurately calculate the odds ratio (OR) of genetic variants. Materials and Methods Using the ACMG guidelines, we reclassified BRCA1 and BRCA2 mutations and variants of unknown significance in 745 Korean patients susceptible to hereditary breast and ovarian cancer compared with 1,314 Korean population controls. Results We observed that the ORs were falsely inflated when we analyzed several variants using non-Korean population data. Our simulation indicated that the number of controls needed for the lower limit of a 95% confidence interval to exceed 1.0 varied according to the frequency of the variant in each patient group, with more than 820 controls needed for a variant existing in 1% of cases. Using a sufficient number of relevant population data, we could efficiently classify variants and identified the BRCA1 p.Leu1780Pro mutation as a possible pathogenic founder mutation in Korean patients. Conclusion Our study suggests that BRCA1 p.Leu1780Pro is a novel pathogenic mutation found in Korean patients. We also determined the optimal number of relevant ethnic controls needed for accurate variant classification according to the ACMG guidelines.
참고문헌 (27)
- Shiovitz S, "Genetics of breast cancer : a topic in evolution", Ann Oncol, 26, pp.1291~1299 (2015)
- Mersch J, "Cancers associated with BRCA1 and BRCA2mutations other than breast and ovarian", Cancer, 121, pp.269~275 (2015)
- Domchek SM, "Multiplex genetic testing for cancer susceptibility: out on the high wire without a net", J Clin Oncol, 31, pp.1267~1270 (2013)
- Easton DF, "A systematic genetic assessment of 1, 433sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes", Am J Hum Genet, 81, pp.873~883 (2007)
- Frank TS, "Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2 : analysis of 10, 000individuals", J Clin Oncol, 20, pp.1480~1490 (2002)
- Lindor NM, "BRCA1", 2 sequence variants of uncertain significance : a primer for providers to assist in discussions and in medical management, 2013, pp.18, 518~524
- Ready K, "Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance", Breast J, 17, pp.210~212 (2011)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Amendola LM, "Performance of ACMG-AMP variantinterpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium", Am J Hum Genet, 98, pp.1067~1076 (2016)
- Jang MA, "Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes", Genet Med, 17, pp.1007~1011 (2015)
- Maxwell KN, "Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer", Am J Hum Genet, 98, pp.801~817 (2016)
- Park KS, "Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer : a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants", Genet Med, 18, pp.1250~1257 (2016)
- Pagano M, "Principles of biostatistics" (2000), Duxbury
- Liu X, "dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs", Hum Mutat, 37, pp.235~241 (2016)
- Jarvik GP, "Consideration of cosegregation in the pathogenicity classification of genomic variants", Am J Hum Genet, 98, pp.1077~1081 (2016)
- Chen VB, "KING(Kinemage, Next Generation) : a versatile interactive molecular and scientific visualization program", Protein Sci, 18, pp.2403~2409 (2009)
- Petrucelli N, "Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2", Genet Med, 12, pp.245~259 (2010)
- Futreal PA, "BRCA1 mutations in primary breast and ovarian carcinomas", Science, 266, pp.120~122 (1994)
- Shattuck-Eidens D, "A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening", JAMA, 273, pp.535~541 (1995)
- Cheon JY, "Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come", Genome Med, 6, pp.121~ (2014)
- Eggington JM, "A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes", Clin Genet, 86, pp.229~237 (2014)
- Choi DH, "Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients", J Clin Oncol, 22, pp.1638~1645 (2004)
- Han SH, "Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer", Clin Genet, 70, pp.496~501 (2006)
- Jang JH, "Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer : the importance of whole-gene sequencing", J Hum Genet, 57, pp.212~215 (2012)
- Huen MS, "BRCA1 and its toolbox for the maintenance of genome integrity", Nat Rev Mol Cell Biol, 11, pp.138~148 (2010)
- Lee MS, "Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays", Cancer Res, 70, pp.4880~4890 (2010)
- Spurdle AB, "BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk", J Med Genet, 49, pp.525~532 (2012)